Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Fenpiverinium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 12/20 | 0.53 |
| ▸ | CHRM2 known ✓ | P08172 | 8/20 | 0.53 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.53 |
| ▸ | CHRM4 known ✓ | P08173 | 3/20 | 0.53 |
| ▸ | CHRM5 known ✓ | P08912 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenpiverinium SCHEMBL1650132 | 0.99 | CHRM3 (0.55) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Buzepide SCHEMBL3498775 | 0.97 | CHRM3 (0.57) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Fenpiverinium SCHEMBL28086315 | 0.85 | OPRM1 (0.43) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Iodide SCHEMBL29558329 | 0.75 | CHRM2 (0.83) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL9295790 | 0.72 | CHRM3 (0.59) | CHRM3CHRM2CHRM1KMT2ACYP2D6 | |
| SCHEMBL10524246 | 0.70 | CHRM3 (0.57) | CHRM3CHRM2CHRM1KMT2ACYP2D6 | |
| SCHEMBL219257 | 0.70 | CHRM2 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Fenpipramide SCHEMBL149504 | 0.70 | CHRM2 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Fenpipramide SCHEMBL11716116 | 0.69 | OPRM1 (0.56) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tricyclamol SCHEMBL30573196 | 0.69 | CHRM2 (0.58) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 457 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171645-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | HOVIONE INTER LTD. (CH) | 2014-06-19 | — | — | US | claimed |
| EP-2691367-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | Hovione Inter Ltd. (CH) | 2014-02-05 | — | — | EP | claimed |
| WO-2012131286-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | HOVIONE INTER. LTD (CH) | 2012-10-04 | — | — | WO | claimed |
| EP-1879578-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2009-05-13 | — | — | EP | claimed |
| EP-1879578-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV Pharmaceutical Inc. (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2006102029-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2006-12-07 | — | — | WO | claimed |
| WO-2006102029-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| WO-2004028548-A2 | INHIBITORS OF THE NITRIX OXIDE SYNTHASE III (NOS III) AS NEUROPROTECTIVE AGENTS | CARBOMER, INC. (US) | 2004-04-08 | — | — | WO | claimed |
| US-20040063612-A1 | Neuroprotective agents | CARBOMER, INC. | 2004-04-01 | — | — | US | claimed |
| CN-1099285-C | Novel Anti-spasmodic composition and process for manufacture thereof | PANACEA BIOTEC LTD (IN) | 2003-01-22 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| CN-1218692-A | Novel Anti-spasmodic composition and process for manufacture thereof | PANACEA BIOTEC LTD (IN) | 1999-06-09 | — | — | CN | claimed |
| US-5876751-A | MIXTURE OF PITOFENONE HYDROCHLORIDE AND FENPIVERINIUM BROMIDE | PANACEA BIOTEC LIMITED (IN) | 1999-03-02 | — | — | US | claimed |
| EP-0868915-A1 | An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium | PANACEA BIOTEC LIMITED (IN) | 1998-10-07 | — | — | EP | claimed |
| JP-10036258-A | — | — | None | — | — | JP | disclosed |
| EP-4168092-B1 | BALLOON CATHETER WITH PRECISION DRUG-ELUTING CAPABILITY | BARD INC C R (US) | 2026-05-27 | — | — | EP | disclosed |
| US-4668684-A | Combination of flupirtin and anticholinergic acting spasmolytic | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1987-05-26 | — | — | US | disclosed |
| EP-0193056-A1 | Combination of flupirtin with spasmolytics having an anticholinergic effect | ASTA Pharma Aktiengesellschaft (DE) | 1986-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171645-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | MGMT, MCL1, TOP2B | CHRM3 3125/4885CHRM2 2607/4885CHRM1 3157/4885 |
| US-20040063612-A1 | Neuroprotective agents | GAP43, NLN, NOS3 | CHRM3 533/4885CHRM2 549/4885CHRM1 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.